Compare Stocks: CVAC, IOVA, RLAY, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
IOVA Iovance Biotherapeutics	$10.25 +2.3%	$6.88	$1.76 ▼ $10.98	$4.54B	0.83	12.76 million shs	22.85 million shs
RLAY Relay Therapeutics	$18.84 -1.8%	$19.30	$4.32 ▼ $21.27	$4.21B	1.69	2.87 million shs	10.08 million shs
TNGX Tango Therapeutics	$21.75 -7.4%	$25.65	$6.69 ▼ $34.39	$3.96B	1.12	2.17 million shs	6.24 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
IOVA Iovance Biotherapeutics	+2.30%	+19.19%	+28.29%	+162.08%	+361.71%
RLAY Relay Therapeutics	-1.82%	-0.16%	-9.16%	+18.64%	+360.64%
TNGX Tango Therapeutics	-7.41%	-8.54%	-13.69%	-22.24%	+185.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
IOVA Iovance Biotherapeutics	$10.25 +2.3%	$6.88	$1.76 ▼ $10.98	$4.54B	0.83	12.76 million shs	22.85 million shs
RLAY Relay Therapeutics	$18.84 -1.8%	$19.30	$4.32 ▼ $21.27	$4.21B	1.69	2.87 million shs	10.08 million shs
TNGX Tango Therapeutics	$21.75 -7.4%	$25.65	$6.69 ▼ $34.39	$3.96B	1.12	2.17 million shs	6.24 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
IOVA Iovance Biotherapeutics	+2.30%	+19.19%	+28.29%	+162.08%	+361.71%
RLAY Relay Therapeutics	-1.82%	-0.16%	-9.16%	+18.64%	+360.64%
TNGX Tango Therapeutics	-7.41%	-8.54%	-13.69%	-22.24%	+185.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
IOVA Iovance Biotherapeutics	2.45	Hold	$9.11	-11.11% Downside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	37.56% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	99.82% Upside

Current Analyst Ratings Breakdown

Latest CVAC, IOVA, RLAY, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$13.00 ➝ $15.00
8/24/2026	IOVA Iovance Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $10.00
8/20/2026	IOVA Iovance Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$4.00 ➝ $7.00
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/18/2026	IOVA Iovance Biotherapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $11.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/14/2026	RLAY Relay Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $31.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	RLAY Relay Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
IOVA Iovance Biotherapeutics	$263.50M	17.62	N/A	N/A	$1.76 per share	5.82
RLAY Relay Therapeutics	$15.35M	268.96	N/A	N/A	$3.27 per share	5.76
TNGX Tango Therapeutics	$62.38M	58.79	N/A	N/A	$2.57 per share	8.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest CVAC, IOVA, RLAY, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
RLAY Relay Therapeutics	N/A	18.27	18.27
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
IOVA Iovance Biotherapeutics	77.03%
RLAY Relay Therapeutics	96.98%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
IOVA Iovance Biotherapeutics	7.80%
RLAY Relay Therapeutics	5.04%
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
RLAY Relay Therapeutics	192	219.14 million	208.10 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

CVAC, IOVA, RLAY, and TNGX Headlines

Recent News About These Companies

Squarepoint Ops LLC Sells 155,357 Shares of Tango Therapeutics, Inc. $TNGX

2 hours ago | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.6% - Here's What Happened

September 18 at 1:00 PM | marketbeat.com

Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

September 18 at 4:07 AM | marketbeat.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

September 10, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 10, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.5% - Still a Buy?

September 9, 2026 | marketbeat.com

Legal & General Group Plc Makes New $2.68 Million Investment in Tango Therapeutics, Inc. $TNGX

September 6, 2026 | marketbeat.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

390,920 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Bank of New York Mellon Corp

September 2, 2026 | marketbeat.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

181,212 Shares in Tango Therapeutics, Inc. $TNGX Purchased by The Manufacturers Life Insurance Company

September 1, 2026 | marketbeat.com

Alyeska Investment Group L.P. Increases Holdings in Tango Therapeutics, Inc. $TNGX

September 1, 2026 | marketbeat.com

Nantahala Capital Management LLC Takes Position in Tango Therapeutics, Inc. $TNGX

August 29, 2026 | marketbeat.com

Jefferies Financial Group Inc. Makes New Investment in Tango Therapeutics, Inc. $TNGX

August 28, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 28, 2026 | marketbeat.com

Seven Fleet Capital Management LP Raises Stock Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Jupiter Topco LLC Invests $157.99 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Boone Capital Management LLC Invests $14.24 Million in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX

August 27, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 4.8% - Here's Why

August 26, 2026 | marketbeat.com

636,070 Shares in Tango Therapeutics, Inc. $TNGX Bought by Connor Clark & Lunn Investment Management Ltd.

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, IOVA, RLAY, and TNGX Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/17/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Iovance Biotherapeutics NASDAQ:IOVA

$10.25 +0.23 (+2.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.22 -0.03 (-0.30%)

As of 09/18/2026 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Relay Therapeutics NASDAQ:RLAY

$18.84 -0.35 (-1.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$18.84 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Tango Therapeutics NASDAQ:TNGX

$21.75 -1.74 (-7.41%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$21.74 -0.02 (-0.07%)

As of 09/18/2026 07:59 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, IOVA, RLAY, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, IOVA, RLAY, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, IOVA, RLAY, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, IOVA, RLAY, and TNGX Company Descriptions

CureVac NASDAQ:CVAC

Iovance Biotherapeutics NASDAQ:IOVA

Relay Therapeutics NASDAQ:RLAY

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, IOVA, RLAY, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, IOVA, RLAY, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, IOVA, RLAY, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, IOVA, RLAY, and TNGX Company Descriptions

CureVac NASDAQ:CVAC

Iovance Biotherapeutics NASDAQ:IOVA

Relay Therapeutics NASDAQ:RLAY

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools